Abstract | INTRODUCTION: AREAS COVERED: EXPERT OPINION: Recent evidence suggests that the ideal SERM profile for one patient may be far from ideal for another. Thus, it could be favorable that different SERMs may be available in the future, each with a somewhat different profile that may be rationally applied to various patients with a spectrum of needs. In this context, lasofoxifene, while retaining some of the adverse effects of other SERMs (i.e., hot flushes and risk of venous thromboembolic events), may offer an improved skeletal efficacy over raloxifene, addressing other postmenopausal conditions, including reduction in breast cancer risk and treatment of vaginal atrophy.
|
Authors | Luigi Gennari, Daniela Merlotti, Konstantinos Stolakis, Ranuccio Nuti |
Journal | Expert opinion on drug discovery
(Expert Opin Drug Discov)
Vol. 6
Issue 2
Pg. 205-17
(Feb 2011)
ISSN: 1746-045X [Electronic] England |
PMID | 22647137
(Publication Type: Journal Article)
|